PRME
Prime Medicine, Inc.
3.20$
+7.7%
vs. previous close
Closing price · As of: Oct 5, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -18.9% | +60.6% | -16.6% | +28.1% | -10.6% | +10.3% | -15.0% | +38.0% | -11.0% | -14.0% | -15.5% | |
| – | -22.5% | +52.2% | -21.5% | +44.1% | -13.9% | -22.7% | -25.9% | +90.8% | -21.7% | -23.9% | -29.8% | |
| – | -5.4% | +126.5% | -41.0% | +112.2% | +54.7% | -49.6% | -41.4% | +32.7% | -11.7% | +1.7% | -26.0% | |
| – | -26.4% | +73.2% | -22.7% | +7.8% | +8.5% | -24.3% | -29.5% | +104.8% | -14.8% | -23.7% | -29.8% | |
| – | – | – | – | – | – | – | +605.9% | – | – | – | – | |
| – | +34.5% | +11.2% | -6.7% | +127.0% | +0.8% | +53.3% | -1.4% | +2.3% | -0.6% | -1.7% | -4.0% | |
| – | +43.3% | -56.7% | -15.1% | +82.5% | +0.2% | -9.7% | -0.5% | +2.7% | +6.9% | -3.1% | -12.7% | |
| – | -17.3% | -27.2% | -22.7% | -14.0% | -19.4% | +89.8% | +5.8% | +6.3% | +5.5% | +5.0% | +5.0% | |
| – | +38.3% | -48.4% | -54.0% | +17.1% | +109.1% | -11.7% | -36.4% | +46.7% | -5.0% | +38.7% | -52.9% | |
| – | -31.4% | +83.2% | -19.4% | -3.6% | -19.2% | -30.2% | -43.1% | +165.9% | -25.3% | -36.5% | -48.1% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +6.0% | +7.3% | +14.1% | +0.5% | -1.0% | +10.4% | -1.3% | +24.2% | -7.3% | +19.0% | +0.1% |
Data as of: October 5, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.